Form 13D/A Definitive Healthcare Corp. For: 1 October By Investing.com
This article from Investing.com reports on a Form 13D/A filing by Definitive Healthcare Corp. for October 1st. The brief entry provides the filing information without further details or analysis, suggesting it's a procedural announcement of interest to investors tracking company disclosures.
Form 13D/A Definitive Healthcare Corp. For: 1 October By Investing.com
This article announces the filing of Form 13D/A by Definitive Healthcare Corp. for October 1st. It briefly mentions the company's stock performance and includes a link to view comments.
A 58.54% holder agrees to restrictions while weighing a transaction with Definitive Healthcare (DH).
Definitive Healthcare Corp. (DH) has signed a confidentiality agreement with Advent International, L.P., which beneficially owns 58.54% of DH shares, to explore a potential transaction. The agreement, signed on September 29, 2026, includes 12-month non-solicitation and standstill provisions, limiting Advent's actions and use of confidential information. Advent International intends to continue discussions with DH's Special Committee and other parties regarding this potential transaction.
Definitive Healthcare Appoints Clay Ritchey as CEO
Definitive Healthcare has announced the appointment of Clay Ritchey as its new Chief Executive Officer and a member of the Board of Directors, effective September 8, 2026. Ritchey brings over 25 years of healthcare expertise and a proven track record of profitable growth, succeeding Kevin Coop. He plans to accelerate the company's growth, leveraging its proprietary datasets, solutions, and an upcoming AI-powered platform to enhance customer value.
Definitive Healthcare Receives $1.02-Per-Share Going-Private Proposal From Advent
Definitive Healthcare Corp. has received a non-binding proposal from Advent International to take the company private at $1.02 per share, acquiring stock and operating-company interests not already owned by Advent or founder Jason Krantz. A special committee of independent directors has been formed to evaluate the offer and potential alternatives, advising shareholders that no decision has been reached and there's no guarantee of a transaction. The proposal aims to privatize the healthcare data and analytics firm, with Advent already holding an ownership stake.
Definitive Healthcare Receives Acquisition Proposal From Advent International
Definitive Healthcare (DH) announced on Wednesday, September 2, 2026, that it has received a non-binding acquisition proposal from Advent International. The full details of the proposal are only available to premium subscribers of MT Newswires.
A $1.02 cash bid could tie up most of Definitive Healthcare (DH) — see how much one insider now reports owning
Definitive Healthcare (DH) Executive Chairman Jason Ronald Krantz has filed a Schedule 13D, reporting a 17.6% beneficial ownership stake in the company. This filing is prompted by a preliminary, non-binding cash acquisition proposal from Advent International to buy all outstanding Class A shares and LLC Units not already owned by Advent and Krantz for $1.02 per share. Krantz is expected to roll over his shares into the surviving company, and while he and Advent could collectively control 66.36% of DH, the transaction is not guaranteed.
Definitive Healthcare stock surges 13% on Advent buyout offer By Investing.com
Definitive Healthcare Corp. (NASDAQ:DH) shares surged 13% after Advent International submitted a non-binding offer to acquire the company for $1.02 per share in cash, representing a 36% premium. The proposal is not subject to financing and requires approval from a Special Committee of independent directors. Concurrently, Definitive Healthcare announced Clay Ritchey as its new CEO, effective September 8, 2026.
Definitive Healthcare receives take-private offer from majority shareholder, names new CEO
Definitive Healthcare has received a take-private offer of $1.02 per share from its majority shareholder, Advent International, which currently owns 58% of the company. A special committee will review this proposal. This development also comes as the company names a new CEO.
Definitive Healthcare stock surges 13% on Advent buyout offer
Definitive Healthcare Corp. (NASDAQ:DH) shares surged 13% after Advent International proposed to acquire the company for $1.02 per share in cash, a 36% premium over its 60-day volume-weighted average. The offer is conditional on founder Jason Krantz rolling over his equity and requires approval from a Special Committee of independent directors. Concurrently, Definitive Healthcare announced Clay Ritchey as its new CEO, succeeding Kevin Coop.
Special Committee of Definitive Healthcare Board Confirms Receipt of Going-Private Proposal from Advent International
The Special Committee of Definitive Healthcare Corp.'s Board of Directors announced it has received a non-binding proposal from Advent International to acquire all outstanding shares not already owned by Advent or the founder for $1.02 per share in cash. The Special Committee, comprised of independent directors, will review the proposal with its advisors to determine the best course of action for the company and its stockholders. No action is required from stockholders at this time, and there is no assurance a transaction will be approved or completed.
Definitive Healthcare receives $1.02 buyout offer from Advent
Definitive Healthcare Corp. (NASDAQ: DH) has received a non-binding buyout proposal from Advent International, L.P. for $1.02 per share in cash, acquiring all outstanding shares not already owned by Advent or the company's founder. A special committee of independent directors has been formed to evaluate the offer and potential alternatives, but no decisions have been made, and shareholders are not required to take action at this time. The company, which provides data and analytics for the healthcare business sector, stated there is no assurance that the transaction will be pursued or completed.
Definitive Healthcare Shares Rise 13% After Advent International Submits $1.02-Per-Share Proposal
Definitive Healthcare Corp. (NASDAQ:DH) shares surged 13% after Advent International proposed to acquire the shares it doesn't already own for $1.02 per share, representing a 36% premium. The non-binding offer assumes founder Jason Krantz will roll over his equity and is not subject to a financing condition. Concurrently, Definitive Healthcare announced Clay Ritchey as its new CEO, succeeding Kevin Coop.
Definitive Healthcare Special Committee Receives Non-Binding Acquisition Proposal from Advent International
Definitive Healthcare Corp. has received a non-binding proposal from Advent International to acquire all outstanding shares of its Class A common stock and LLC interests for $1.02 per share. A Special Committee of independent directors will review the proposal with legal and financial advisors, advising shareholders that no immediate action is required. The company emphasizes that there's no guarantee the transaction will be approved or consummated.
Definitive Healthcare stock surges 13% on Advent buyout offer By Investing.com
Definitive Healthcare Corp. (NASDAQ:DH) shares surged 13% after Advent International proposed to acquire the company for $1.02 per share in cash, representing a 36% premium to its 60-day volume-weighted average price. The offer is non-binding and contingent on approval from a Special Committee of independent directors, with Executive Chairman Jason Krantz rolling over his equity. Separately, Definitive Healthcare appointed Clay Ritchey as its new CEO.
Special Committee of Definitive Healthcare Board Confirms Receipt of Going-Private Proposal from Advent International
The special committee of Definitive Healthcare's Board of Directors announced the receipt of a non-binding proposal from Advent International to acquire all outstanding shares of the company's Class A common stock and Definitive OpCo Units for $1.02 per share. The committee, consisting of independent directors, will evaluate the proposal with its advisors to determine the best course of action for the company and its stockholders. Definitive Healthcare emphasizes that no action is required by stockholders at this time, and there's no guarantee a transaction will be approved or completed.
Advent makes non-binding cash bid for all Definitive Healthcare (NASDAQ: DH) shares
Advent International has submitted a preliminary, non-binding offer to acquire all outstanding shares of Definitive Healthcare (DH) not already owned by Advent funds and founder Jason Krantz for $1.02 per share in cash. If the proposal proceeds, Advent and Krantz would collectively hold 66.36% of Definitive Healthcare's common stock. The transaction is subject to approval by a Special Committee of DH's Board and regulators, with Advent reserving the right to modify or withdraw the offer.
Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Rating of "Reduce" by Analysts
Definitive Healthcare Corp. (NASDAQ:DH) has received a consensus "Reduce" rating from analysts, with an average 12-month price target of $1.47. Despite beating EPS estimates in its latest quarterly report, the company missed revenue expectations and maintains a negative net margin. Institutional investors hold a significant majority of the stock, with several increasing their positions.
Definitive Healthcare posts a stellar 41.44% ROIC, far surpassing its 5.78% capital cost.
Definitive Healthcare Corp. has achieved an exceptional Return on Invested Capital (ROIC) of 41.44%, significantly outperforming its Weighted Average Cost of Capital (WACC) of 5.78%. This indicates robust financial health and efficient operations, generating more than seven times the value for every dollar invested. The company's strong performance positions it as a leader in the healthcare intelligence sector, signaling a promising outlook for investors.
Definitive Healthcare Launches Turbo AI Healthcare Intelligence Platform
Definitive Healthcare (Nasdaq: DH) reported Q2 2026 revenue of $55.2 million, a 9% decrease year-over-year, but within guidance. The company's net loss improved, and it launched Turbo, an AI-powered healthcare intelligence platform. Definitive Healthcare also provided guidance for Q3 and full-year 2026, anticipating continued revenue and adjusted EBITDA in line with expectations, despite a negative market reaction to the Q2 earnings report.
Definitive Healthcare Q2 2026 slides: profit beats amid revenue decline
Definitive Healthcare (NASDAQ:DH) exceeded profitability guidance in Q2 2026 despite a 9% year-over-year revenue decline, driven by strong cost management. The company reported adjusted operating income and adjusted EBITDA above expectations, leading to a 3.08% rise in shares after hours. Definitive Healthcare also raised its full-year profit outlook while tightening revenue guidance, signaling confidence in its operational efficiency amidst market challenges.
Definitive Healthcare revenue falls 9% in Q2, cash flow holds
Definitive Healthcare reported a 9% revenue decline in Q2 2026, reaching $55.2 million, but maintained strong unlevered free cash flow of $11.6 million. Despite a fall in adjusted net income and EBITDA, the company highlighted strategic wins and the launch of its AI-powered platform, Turbo. Definitive Healthcare also provided full-year revenue guidance between $220.0 million and $222.0 million, emphasizing a focus on stabilizing profitability while investing in growth initiatives.
Form 8K Definitive Healthcare Corp For: 10 August By Investing.com
This article reports on Definitive Healthcare Corp's Form 8K filing for August 10th. The brief news item also notes a -7.85% drop in Definitive Healthcare's stock (DH) and was published by Investing.com.
Definitive Healthcare Corp. Q2 2026: Revenue $55.2M, EPS $(0.05) — 10-Q Summary
Definitive Healthcare Corp. reported Q2 2026 results, showing revenue of $55.2M, a 9% year-over-year decline, and a narrowed net loss of $(5.4)M, with EPS at $(0.05). The company experienced customer churn, particularly among smaller accounts, and initiated a restructuring plan to cut costs. They also launched an AI-powered platform pilot and addressed claims data source disruptions.
Form 8K Definitive Healthcare Corp For: 10 August By Investing.com
This article announces that Definitive Healthcare Corp has filed a Form 8K on August 10. The filing is provided by Investing.com, a financial markets news source. The content primarily consists of the announcement itself and includes stock market data and other news headlines from Investing.com.
Definitive Healthcare (DH) books $197M goodwill hit and faces Nasdaq bid-price risk
Definitive Healthcare (DH) reported a significant net loss of $199.8 million for the six months ended June 30, 2026, primarily due to a non-cash $197.2 million goodwill impairment charge following sustained stock price declines. The company also received a Nasdaq notice for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day remediation period. Despite these challenges, DH maintained positive operating cash flow and a strong cash position, while also implementing a restructuring plan and resolving an acquisition earnout dispute.
Definitive Healthcare (Nasdaq: DH) Q2 2026 revenue hits $55.2M amid large write-down
Definitive Healthcare (Nasdaq: DH) reported Q2 2026 revenue of $55.2 million, a decrease from Q2 2025, and a GAAP net loss of $7.5 million. The company incurred a significant goodwill impairment charge of $197.2 million for the first half of 2026, leading to a year-to-date net loss of $199.8 million. Despite declining top-line and adjusted earnings, the company highlighted strong operating cash flow and improved net dollar retention, while also providing guidance for Q3 and full-year 2026.
Definitive Healthcare Reports Financial Results for Second Quarter 2026
Definitive Healthcare (Nasdaq: DH) reported its second-quarter 2026 financial results, with revenue of $55.2 million, a 9% decrease year-over-year, but profits surpassing expectations. The company highlighted improvements in net dollar retention and the launch of its AI-powered healthcare intelligence platform, Turbo. Definitive Healthcare also provided financial guidance for the third quarter and full year 2026, anticipating continued growth and profitability.
Definitive Healthcare Launches Early Adopter Program for New AI-Powered Healthcare Intelligence Platform
Definitive Healthcare (Nasdaq: DH) has announced an early adopter program for its new AI-powered healthcare intelligence platform, providing select organizations with early access. The platform integrates claims, provider, consumer, and expert data with conversational AI to surface insights, optimize market opportunities, and improve decision-making. The company aims for general availability later in 2026, incorporating feedback from participants spanning health systems, life sciences, and other healthcare-selling industries.
Definitive Healthcare Corp. (DH) chair has 12,166 shares withheld for tax
Definitive Healthcare Corp.'s Executive Chairman and 10% owner, Jason Ronald Krantz, had 12,166 Class A common shares withheld on August 1, 2026, to cover tax obligations from the vesting of Restricted Stock Units (RSUs) at a price of $0.6823 per share. Following this transaction, Krantz directly holds 1,189,272 Class A shares and indirectly owns 450,000 shares through DH Holdings. This disposition was for tax purposes and not an open-market sale.
Definitive Healthcare (DH) CFO has 1,881 shares withheld to cover RSU taxes
Definitive Healthcare Corp. reported that its Chief Financial Officer, Casey Heller, had 1,881 shares of Class A Common Stock withheld on August 1, 2026. This action was taken to satisfy tax withholding obligations related to the vesting of previously reported Restricted Stock Units (RSUs). Following this transaction, Heller directly holds 1,839,595 shares of the company's stock.
Definitive Healthcare to report Q2 2026 earnings on August 10 with a live webcast and call.
Definitive Healthcare Corp. announced it will release its second-quarter financial results for the period ending June 30, 2026, on August 10, after the market closes. The company will host a conference call and webcast at 5:00 PM ET to discuss these results, which will be accessible via their investor relations website. A replay of the event will be available until September 9, 2026, providing investors with an opportunity to review the company's performance and outlook.
Definitive Healthcare Announces Timing of Its Second Quarter 2026 Financial Results Conference Call and Webcast
Definitive Healthcare Corp. announced it will report its second quarter 2026 financial results on Monday, August 10, 2026, after market close. The company will host a conference call and webcast at 5:00 PM ET to discuss the results. Interested parties can access the live audio webcast through the company's Investor Relations website or
Definitive Healthcare Announces Timing of Its Second Quarter 2026 Financial Results Conference Call and Webcast
Definitive Healthcare Corp. (Nasdaq: DH) announced it will release its second-quarter financial results for 2026 on Monday, August 10, 2026, after market close. The company will host a conference call and webcast at 5:00 PM ET to discuss these results. A replay of the call will be available until September 9, 2026.
Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
Definitive Healthcare Corp. (Nasdaq: DH) announced inducement awards granted to Srinivas Attipalli, the new SVP and Head of AI & Data - Product. Mr. Attipalli received 1,063,830 time-based restricted stock units (RSUs), effective July 24, 2026, as an inducement to his employment. These RSUs will vest over time, starting June 1, 2027, in accordance with the company's 2023 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
Definitive Healthcare Corp. Announces Appointment of Srinivas Attipalli as Head of Ai & Data - Product
Definitive Healthcare Corp. announced the appointment of Srinivas Attipalli as Head of AI & Data - Product. The company, which specializes in healthcare commercial intelligence, uses AI and machine learning to transform data into insights. This new appointment is expected to further enhance their data platform and analytical capabilities.
Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Recommendation of "Reduce" from Brokerages
Nine brokerages have assigned Definitive Healthcare Corp. (NASDAQ:DH) an average "Reduce" rating, with a consensus 12-month price target of $2.47 across analysts actively covering the stock. The company's shares opened at $0.68, significantly below its 52-week high, while institutional investors hold a substantial 98.67% of its stock. Definitive Healthcare recently reported strong quarterly earnings, surpassing analyst estimates for both adjusted EPS and revenue.
Definitive Healthcare (NASDAQ:DH) Upgraded at Wall Street Zen
Wall Street Zen has upgraded Definitive Healthcare (NASDAQ:DH) from "hold" to "buy," despite a cautious broader analyst view with an average rating of "Reduce" and a target price of $2.47. The stock is trading near its 52-week low at $0.68, with a market capitalization of $72.1 million. Definitive Healthcare recently exceeded earnings and revenue expectations in its latest quarter and provided Q2 and full-year 2026 guidance.
DH|Definitive Healthcare Corp|Price:0.677|Chg%:-0.008
Definitive Healthcare Corp (DH) is currently trading at $0.683, down 0.42%. Despite healthy fundamentals and high growth potential, its stock price has seen significant declines over the past year. Analysts mostly rate the stock as "Hold" with a target price of $2.20, indicating a potential upside of over 200%.
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX) and MindWalk Holdings (HYFT)
Analysts have provided optimistic outlooks for healthcare companies Quest Diagnostics (DGX) and MindWalk Holdings (HYFT). Quest Diagnostics received a Buy rating from William Blair with a $231.40 average price target, while MindWalk Holdings also secured a Buy rating from JonesTrading and H.C. Wainwright, with a $5.00 price target, suggesting a significant upside. Both companies are viewed positively by analysts in the Healthcare sector.
Definitive Healthcare (DH) CEO has shares withheld to cover RSU taxes
Definitive Healthcare Corp. CEO Kevin Coop reported a tax-related share disposition. The company withheld 37,593 shares of Class A common stock at $0.80 per share to cover Coop’s tax withholding obligations upon the settlement of restricted stock units (RSUs). This transaction was not an open-market sale, and following the withholding, Coop directly owns 4,975,229 shares of Class A common stock.
[Form 4] Definitive Healthcare Corp. Insider Trading Activity
Definitive Healthcare Corp.'s Chief Legal Officer, Jonathan Paris, had 30,591 shares of Class A Common Stock withheld at $0.80 per share to cover tax obligations related to vested Restricted Stock Units (RSUs). Following this transaction, Paris directly holds 872,263 shares of Class A Common Stock. The filing, categorized as "Neutral" in impact and sentiment, details this non-market tax-withholding disposition.
July 2026's Spotlight On Promising Penny Stocks
This article highlights three promising penny stocks for July 2026: Definitive Healthcare (DH), PMV Pharmaceuticals (PMVP), and Granite Point Mortgage Trust (GPMT). Each company is analyzed based on its financial health, market capitalization, operational specifics, and potential for growth, despite the inherent risks associated with penny stocks. The piece emphasizes the importance of robust financials and a clear growth path when considering such investments.
Definitive Healthcare Corp.(NasdaqGS:DH) added to Russell Microcap Value Benchmark Index
Definitive Healthcare Corp. (NasdaqGS:DH) has been added to the Russell Microcap Value Benchmark Index. This news comes alongside other recent developments for the company, including being dropped from the Russell 2000 Value Benchmark and Russell 2000 Dynamic Index,
Definitive Healthcare Corp.(NasdaqGS: DH) dropped from Russell 2000 Value Benchmark
Definitive Healthcare Corp. (NasdaqGS: DH) has been removed from the Russell 2000 Value Benchmark, as announced on June 29, 2026. This news comes alongside several other index changes for the company, including being added to the Russell Microcap Value Benchmark Index and dropped from various Russell 2000 and 3000 indices. The company, which provides healthcare commercial intelligence through its SaaS platform, recently saw its price target cut by BofA due to intensifying competitive pressures.
Why is Definitive Healthcare stock climbing today? By Investing.com
Definitive Healthcare Corp (DH) stock surprisingly climbed 5.1% in after-hours trading despite a dramatic double downgrade from BofA Securities, which cited concerns over commoditization and AI in the healthcare data market. The bounce appears to be a technical relief rally, as the stock hit a 52-week low and BofA's new price target, while pessimistic, was marginally above the after-hours price, potentially clearing an overhang of uncertainty.
Definitive Healthcare Corp.(NasdaqGS: DH) dropped from Russell 3000 Index
Definitive Healthcare Corp. (NasdaqGS: DH) has been dropped from the Russell 3000 Index, as well as several other Russell indices including the Russell 2000 and Russell 2500 Value Benchmarks. Concurrently, the company was added to the Russell Microcap Value Benchmark Index and the Russell Microcap Index. This follows a period where the company's shares experienced a significant drop, and analysts like BofA downgraded the stock due to intensifying competitive pressures.
Definitive Healthcare Corp.(NasdaqGS: DH) dropped from Russell 2500 Index
Definitive Healthcare Corp. (NasdaqGS: DH) has been removed from the Russell 2500 Index, as announced on June 28, 2026. This follows a series of other re-indexings, including its addition to the Russell Microcap Value Benchmark Index and removal from several other Russell indices on June 29, 2026. The company, which provides healthcare commercial intelligence, also saw a downgrade from BofA due to rising competitive pressures.
Definitive Healthcare Corp. Class A Actuals & Estimates (NASDAQ:DH)
This article provides an overview of Definitive Healthcare Corp. (NASDAQ: DH) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates, upcoming earnings dates, and current financial metrics like revenue, net income, and EBITDA.
Definitive Healthcare (NASDAQ: DH) warned by Nasdaq on sub-$1 bid price
Definitive Healthcare (NASDAQ: DH) has received a notice from Nasdaq for failing to meet the minimum $1.00 per share bid price requirement. The company's stock traded below this threshold for 30 consecutive business days, from May 6, 2026, to June 17, 2026. Definitive Healthcare has 180 calendar days, until December 15, 2026, to regain compliance, potentially through actions like a reverse stock split.
